CU24622B1 - Derivados de tiadiazina como moduladores del receptor nicotínico de acetilcolina alfa7 - Google Patents

Derivados de tiadiazina como moduladores del receptor nicotínico de acetilcolina alfa7

Info

Publication number
CU24622B1
CU24622B1 CU2020000109A CU20200109A CU24622B1 CU 24622 B1 CU24622 B1 CU 24622B1 CU 2020000109 A CU2020000109 A CU 2020000109A CU 20200109 A CU20200109 A CU 20200109A CU 24622 B1 CU24622 B1 CU 24622B1
Authority
CU
Cuba
Prior art keywords
modulators
acetylcholine receptor
nicotinic acetylcholine
thiadiazine derivatives
alpha7 nicotinic
Prior art date
Application number
CU2020000109A
Other languages
English (en)
Other versions
CU20200109A7 (es
Inventor
János Éles
Eszter Gábor
Erszébet Jablonkai
István Ledneczki
György István Lévay
Zsolt Némethy
József Levente Petro
György Selényi
Pál Tapolcsányi
András Visegrádi
Original Assignee
Richter Gedeon Nyrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Nyrt filed Critical Richter Gedeon Nyrt
Publication of CU20200109A7 publication Critical patent/CU20200109A7/es
Publication of CU24622B1 publication Critical patent/CU24622B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C07D285/16—Thiadiazines; Hydrogenated thiadiazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

<p>La presente invención se refiere a compuestos de tiadiazina farmacológicamente activos de fórmula (I),</p> <p>ESPACIO PARA LA FÓRMULA</p> <p>útiles como moduladores de Ia actividad del receptor nicotínico de acetilcolina α7 en un sujeto mamífero.</p>
CU2020000109A 2018-07-13 2019-07-12 Derivados de tiadiazina como moduladores del receptor nicotínico de acetilcolina alfa7 CU24622B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HUP1800249A HU231414B1 (hu) 2018-07-13 2018-07-13 Tiadiazin származékok
PCT/IB2019/055949 WO2020012423A1 (en) 2018-07-13 2019-07-12 Thiadiazine derivatives

Publications (2)

Publication Number Publication Date
CU20200109A7 CU20200109A7 (es) 2021-08-06
CU24622B1 true CU24622B1 (es) 2022-09-08

Family

ID=89992726

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2020000109A CU24622B1 (es) 2018-07-13 2019-07-12 Derivados de tiadiazina como moduladores del receptor nicotínico de acetilcolina alfa7

Country Status (23)

Country Link
US (2) US12194050B2 (es)
EP (1) EP3820865A1 (es)
JP (2) JP7440486B2 (es)
KR (1) KR20210033003A (es)
CN (1) CN112424198A (es)
AR (1) AR115783A1 (es)
AU (1) AU2019300515B2 (es)
BR (1) BR112020027016A2 (es)
CA (1) CA3104264A1 (es)
CL (1) CL2021000081A1 (es)
CO (1) CO2021001224A2 (es)
CU (1) CU24622B1 (es)
EA (1) EA202190246A1 (es)
GE (2) GEP20237459B (es)
HU (1) HU231414B1 (es)
IL (1) IL279939B2 (es)
MX (1) MX2021000461A (es)
MY (1) MY207757A (es)
PE (1) PE20210465A1 (es)
PH (1) PH12021550007A1 (es)
SG (1) SG11202012769QA (es)
TW (1) TWI827628B (es)
WO (1) WO2020012423A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4103191A4 (en) * 2020-02-14 2024-03-06 University of Pittsburgh - of the Commonwealth System of Higher Education HEAT SHOCK PROTEIN MODULATORS AND THERAPEUTIC AGENTS FOR HUNTINGTON'S DISEASE
US12649738B2 (en) 2020-03-26 2026-06-09 Richter Gedeon Nyrt. 1,3-dihydro-2H-pyrrolo[3,4-c]pyridine derivatives as GABAA α5 receptor modulators
TWI901650B (zh) 2020-03-26 2025-10-21 匈牙利商羅特格登公司 啶及吡啶并〔３，４－ｃ〕嗒衍生物
CN111454232B (zh) * 2020-05-30 2021-11-23 南方医科大学 一种1,3,4-噻二嗪类化合物及其应用
HU231691B1 (hu) 2021-09-29 2025-10-28 Richter Gedeon Nyrt GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006016548A1 (ja) 2004-08-09 2006-02-16 Eisai R & D Management Co., Ltd. ヘテロ環化合物を含有する新規な抗マラリア剤
AU2006290814B2 (en) 2005-09-13 2012-06-07 Janssen Pharmaceutica N.V. 2-aniline-4-aryl substituted thiazole derivatives
ES2274729B1 (es) 2005-11-11 2008-06-01 Consejo Superior Investig. Cientificas Derivados de 5-carboxilato y 5-carboxamida 2-sustituidos de 1,1-dioxo-1,2,6-tiadiazina con propiedades cannabinoides.
CA2672960A1 (en) 2006-12-20 2008-07-10 Schering Corporation Novel jnk inhibitors
KR101178674B1 (ko) 2007-10-04 2012-08-30 에프. 호프만-라 로슈 아게 사이클로프로필 아릴 아마이드 유도체 및 이의 용도
KR101186704B1 (ko) 2007-10-04 2012-09-27 에프. 호프만-라 로슈 아게 테트라졸-치환된 아릴 아마이드 유도체 및 이의 용도
US8536221B2 (en) 2008-02-07 2013-09-17 Abbvie Inc. Amide derivatives as positive allosteric modulators and methods of use thereof
AR070936A1 (es) 2008-03-19 2010-05-12 Janssen Pharmaceutica Nv 1,2,4 -triazoles trisustituidos
EP2110377A1 (en) 2008-04-15 2009-10-21 DAC S.r.l. Spirocyclic derivatives as histone deacetylase inhibitors
ES2392796T3 (es) 2008-04-17 2012-12-13 Proximagen Limited Moduladores de tipo indol del receptor nicotínico de acetilcolina alfa-7
JP5486591B2 (ja) 2008-05-09 2014-05-07 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ アセチルコリン受容体モジュレーターとしての三置換ピラゾール
US8530483B2 (en) 2008-05-30 2013-09-10 Merck Sharp & Dohme Corp. Substituted azabenzoxazoles
CN102666540A (zh) * 2009-10-13 2012-09-12 Msd欧斯股份有限公司 用于治疗乙酰胆碱受体相关疾病的稠合吖嗪衍生物
PT3511330T (pt) 2009-12-31 2020-12-24 Hutchison Medipharma Ltd Intermediário sintético útil na preparação de inibidores de triazolopiridina c-met
US8829026B2 (en) 2010-10-01 2014-09-09 Raqualia Pharma Inc. Sulfamoyl benzoic acid heterobicyclic derivatives as TRPM8 antagonists
EP2670744B1 (en) 2011-02-03 2015-05-27 Lupin Limited Pyrrole derivatives used as modulators of alpha7 nachr
US9617210B2 (en) * 2013-03-13 2017-04-11 Lupin Limited Pyrrole derivatives as alpha 7 NACHR modulators
US9840481B2 (en) * 2016-03-22 2017-12-12 Merck Sharp & Dohme Corp. Allosteric modulators of nicotinic acetylcholine receptors
JP7041141B2 (ja) 2016-11-01 2022-03-23 メルク・シャープ・アンド・ドーム・コーポレーション 置換された二環式ヘテロアリール系ニコチン性アセチルコリン受容体アロステリック調節剤
CA3046805A1 (en) 2016-12-14 2018-06-21 89Bio Ltd. Spiropiperidine derivatives
BR112019018230A2 (pt) * 2017-03-02 2020-07-21 Assembly Biosciences, Inc. compostos de sulfamida cíclica e métodos de sua utilização
HU231333B1 (hu) 2018-07-13 2023-01-28 Richter Gedeon Nyrt Spirokromán származékok

Also Published As

Publication number Publication date
TW202019431A (zh) 2020-06-01
MX2021000461A (es) 2021-06-23
TWI827628B (zh) 2024-01-01
JP7440486B2 (ja) 2024-02-28
US12194050B2 (en) 2025-01-14
JP2021529813A (ja) 2021-11-04
IL279939B1 (en) 2024-09-01
GEP20237459B (en) 2023-01-25
CO2021001224A2 (es) 2021-02-17
AU2019300515B2 (en) 2025-01-23
IL279939A (en) 2021-03-01
GEAP202215558A (en) 2022-07-25
PH12021550007A1 (en) 2021-09-20
WO2020012423A1 (en) 2020-01-16
BR112020027016A2 (pt) 2021-04-06
JP2024056879A (ja) 2024-04-23
CA3104264A1 (en) 2020-01-16
CL2021000081A1 (es) 2021-10-29
CN112424198A (zh) 2021-02-26
EP3820865A1 (en) 2021-05-19
US20210267993A1 (en) 2021-09-02
US20250064823A1 (en) 2025-02-27
MY207757A (en) 2025-03-17
CU20200109A7 (es) 2021-08-06
IL279939B2 (en) 2025-01-01
PE20210465A1 (es) 2021-03-08
EA202190246A1 (ru) 2021-04-20
SG11202012769QA (en) 2021-02-25
HU231414B1 (hu) 2023-08-28
AR115783A1 (es) 2021-02-24
KR20210033003A (ko) 2021-03-25
AU2019300515A1 (en) 2021-02-11
HUP1800249A2 (en) 2020-01-28

Similar Documents

Publication Publication Date Title
CO2018007738A2 (es) Derivados de tiohidantoína sustituidos como antagonistas del receptor de andrógenos
TR201904340T4 (tr) Yeni bileşikler.
UY36251A (es) Procedimiento para la preparación de (4s)- 4-(4-ciano-2-metoxifenilo)-5-toxi-2,8-dimetilo-1,4-dihidro-1,6-naftiridin-3-carbox-amida y su purificación para su uso como principio activo farmacéutico
CU20200108A7 (es) Derivados de espirocromano como moduladores del receptor de acetilcolina nicotínica alfa7
CU24517B1 (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
CL2017003127A1 (es) Derivados de 2,3-dihidro-4h-1,3-benzoxazin-4-ona como moduladores de receptor muscarinico m1 colinergico.
BR112016009630A8 (pt) receptores de farnesoide x, seus usos, composição farmacêutica, e combinação
BR112016025423A2 (pt) compostos e composições como agonistas de receptores do tipo toll 7
MX2019010446A (es) Compuestos de anillos fusionados biciclicos derivados de piridilo como inhibidores de fgfr4.
BR112017009657A2 (pt) análogos de ácidos biliares como agonistas de fxr/tgr5 e métodos de uso dos mesmos
ECSP13012612A (es) Derivados de quinazolin-4-(3h)-ona utilizados como inhibidores de p13 cinasa
EA201492023A1 (ru) Регуляторы пути комплемента и их применение
UY34778A (es) ?COMPUESTOS DE HEXAHIDROPIRANO[3,4-d][1,3]TIAZIN-2-AMINA HETEROCÍCLICOS SUSTITUÍDOS?.
UY35381A (es) Pirrolotriazinas como inhibidores del canal del ion potasio
CR20150296A (es) Novedosos derivados de bencimidazol como antagonistas de ep4
BR112016002459A2 (pt) Derivados de benzimidazolil-metil ureia como agonistas receptores de alx
UY36348A (es) Derivados de benzotiofenilo sustituidos como agonistas del gpr40 para el tratamiento de la diabetes tipo ii
UY34612A (es) ?procedimiento para la preparación de derivados de isoxazolina azetidina quirales como agentes antiparasitarios?.
EA201591815A1 (ru) Бицикло [2.2.2] кислоты - модуляторы gpr120
GEP20166444B (en) Epoxyeicosatrienoic acid analogs and methods of making and using the same
BR112017016817A2 (pt) derivados heterocíclicos formilados como inibidores de fgfr4
MX387775B (es) Derivado de 2-acilaminotiazol o sal del mismo.
CR20150144A (es) Derivados de etinilo como moduladores del receptor de actividad mglur5
NI201200195A (es) Procedimiento de preparación de la sal de l - arginina de perindoprilo
BR112016018418A2 (pt) Composto, uso do mesmo, e composição farmacêutica